Study findings from Anaconda Biomed regarding the ANAIS study have been published in the American Journal of Neuroradiology
Anaconda Biomed's ANA5 Funnel Catheter Shows Promising Results in Stroke Treatment
Anaconda Biomed, a leading medical device company, has made significant strides in neurovascular procedures with the development of the ANA5 funnel catheter. This novel device, designed to work in conjunction with stent retrievers, enables temporary local flow restriction upon deployment.
The ANA5 catheter, with its large lumen matching the diameter of the target artery, has shown promise in improving neurological outcomes after stroke. Dr. Alejandro Tomasello, the principal investigator, has stated that the advancements may potentially lead to improved neurological outcomes.
Anaconda Biomed has recently appointed a new CEO, signaling a new phase in the company's journey. The company has also enrolled the first U.S. patient in the ATHENA study, a clinical trial assessing the safety and efficacy of the ANA funnel catheter in endovascular treatment of acute ischemic stroke.
The ATHENA trial, however, is currently without updated findings or status, as no recent data, news, or updates regarding this clinical trial or the device in question were found in the provided search results. For up-to-date information, it is recommended to consult clinical trial registries like ClinicalTrials.gov, recent publications in medical journals, or official communications from Anaconda Biomed.
Meanwhile, the ANA funnel catheter's safety and performance have been evaluated in the ANAIS Study. Conducted prospectively across three centers in Spain, the ANAIS Study demonstrated high rates of reperfusion and first-pass success with a strong safety profile. In the ICA C2-C3 segment, when the ANA device was deployed and continuous aspiration was applied, first pass effect (eTICI 2c-3) was achieved in 83 percent of the cases. The results of the ANAIS Study have been published in the American Journal of Neuroradiology.
During acute ischemic stroke thrombectomy procedures, the ANA5 catheter may enhance clot removal, especially in combination with stent retrievers. The catheter features a radiopaque, self-expanding funnel covered with a continuous sealing coating.
While the ATHENA trial continues, the promising results from the ANAIS Study suggest that the ANA5 funnel catheter could play a significant role in stroke treatment, offering a potential breakthrough in neurovascular procedures.
The ANA5 funnel catheter, with its potential to improve neurological outcomes in acute ischemic stroke, could contribute to health-and-wellness by addressing medical-conditions such as neurological-disorders. The promising results from the ANAIS Study and the ongoing ATHENA trial indicate a possible breakthrough in science, particularly in the field of stroke treatment.
